Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20893422 | 0.81 | HTR2A (0.38) | HTR2AHTR2CHTR2BSIGMAR1POLB | |
| SCHEMBL15739458 | 0.81 | POLB (0.47) | HTR2AHTR2CHTR2BSIGMAR1POLB | |
| SCHEMBL29185139 | 0.81 | POLB (0.47) | HTR2AHTR2CHTR2BSIGMAR1POLB | |
| SCHEMBL14617840 | 0.80 | HCAR2 (0.44) | HTR2AHTR2CHTR2BSIGMAR1POLB | |
| SCHEMBL17426067 | 0.80 | ALDH1A1 (0.33) | HTR2AHTR2CHTR2BSIGMAR1POLB | |
| SCHEMBL18904835 | 0.80 | METAP1 (0.33) | HTR2AHTR2CHTR2BSIGMAR1POLB | |
| SCHEMBL21101596 | 0.79 | KDM4E (0.33) | HTR2AHTR2CHTR2BSIGMAR1BTK | |
| SCHEMBL25678839 | 0.76 | TDP1 (0.33) | — | |
| SCHEMBL20415397 | 0.76 | MAPT (0.45) | POLB | |
| SCHEMBL15715697 | 0.74 | DPP7 (0.39) | HTR2AHTR2CHTR2BSIGMAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022109487-A1 | SPIROCYCLIC-SUBSTITUTED 6,7-DIHYDRO-PYRANO[2,3-D]PYRIMIDINE INHIBITORS OF KRAS G12C MUTANT | MERCK SHARP & DOHME CORP. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022109485-A1 | 6,7-DIHYDRO-PYRANO[2,3-D]PYRIMIDINE INHIBITORS OF KRAS G12C MUTANT | MERCK SHARP & DOHME CORP. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2021086833-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | MERCK SHARP & DOHME CORP. (US) | 2021-05-06 | — | — | WO | disclosed |
| WO-2021057998-A1 | PREPARATION METHOD FOR PYRROLOAMINOPYRIDAZINONE COMPOUND | 上海森辉医药有限公司 | 2021-04-01 | — | — | WO | disclosed |
| US-10323037-B2 | Aminopyridazinone compounds as protein kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-06-18 | — | — | US | disclosed |
| US-9951077-B2 | Aminopyridazinone compounds as protein kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-04-24 | — | — | US | disclosed |
| US-20170152264-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152264-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | SSB, MAPKAPK5, BCL9 | HTR2A 3926/4885HTR2C 3942/4885HTR2B 3469/4885 |
| US-10323037-B2 | Aminopyridazinone compounds as protein kinase inhibitors | SSB, MAPKAPK5, BCL9 | HTR2A 3926/4885HTR2C 3942/4885HTR2B 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.